Condition: Stage IA Lung Cancer · Sponsor: Hangzhou Broncus Medical Co., Ltd.
The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.
This description comes directly from the study's public registry record.
Jiayuan Sun, MD, PhD · 86-021-22200000 · xkyyjysun@163.com
Always discuss trial participation with your own doctor first.
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06052098